Bristol-Myers Squibb
BMY
$0.13 (-0.26%)
1D
1W
3M
1Y
5Y
ALL
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 1 hours ago • BMY
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and ContraindicationsZacks Investment Research • 7 hours ago • BMY
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?Zacks Investment Research • 10 hours ago • BMY
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseBusiness Wire • 1 day ago • BMY
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTZacks Investment Research • 1 day ago • BMY
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.